-

Alnylam to Webcast Presentations at Upcoming December Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following upcoming investor conferences:

  • Piper Sandler 38th Annual Healthcare Conference on Thursday, December 3, 2026, at 8:30 a.m. ET in New York City
  • Citi’s 2026 Global Healthcare Conference on Thursday, December 3, 2026, at 10:20 a.m. ET in Miami

A live audio webcast of each presentation will be available on the Investors section of the Company’s website at www.alnylam.com/events. A replay will be posted on the website within 48 hours after each event.

About Alnylam Pharmaceuticals

Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel Prize-winning science of RNAi, delivering critical breakthroughs and seven approved medicines. Alnylam has medicines available in more than 70 countries and a robust and rapidly expanding pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, visit www.alnylam.com or follow Alnylam on X, LinkedIn, Facebook, Instagram, or YouTube.

Contacts

Alnylam Pharmaceuticals, Inc.
Media
media@alnylam.com

Investors
investors@alnylam.com

Alnylam Pharmaceuticals, Inc.

NASDAQ:ALNY

Release Versions

Contacts

Alnylam Pharmaceuticals, Inc.
Media
media@alnylam.com

Investors
investors@alnylam.com

More News From Alnylam Pharmaceuticals, Inc.

Alnylam Collaborator Regeneron Secures FDA Approval of Livsayis™ (cemdisiran), the Seventh FDA-Approved Therapeutic from Alnylam's RNAi Platform in Less Than Nine Years

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration (FDA) has approved Livsayis™ (cemdisiran), an Alnylam-discovered RNAi therapeutic that was developed and will be commercialized by Regeneron, for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive. This marks the seventh Alnylam-discovered RNAi...

Alnylam Collaborator Regeneron Advances CIDEBsiRNA with Promising First-in-Human Results in Patients with MASLD

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that its collaborator, Regeneron Pharmaceuticals, Inc. shared initial results from a first-in-human trial that demonstrated a single subcutaneous dose of CIDEBsiRNA (previously known as ALN-CIDEB) rapidly normalized liver fat and improved liver injury markers in patients with metabolic-dysfunction-associated steatotic liver disease (MASLD) with effects that wer...

Alnylam Announces Five-Year HELIOS-B Data Demonstrating Sustained Benefit of AMVUTTRA® (vutrisiran) in ATTR-CM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the American Heart Association (AHA) Scientific Sessions 2026, adding to the robust body of evidence demonstrating the strength of RNAi-powered TTR silencing with AMVUTTRA® (vutrisiran). The analyses, including data from the HELIOS-B Phase 3 two-year open-label extension (OLE) period, show that patients with transthyretin amyloidosis with cardiomyop...
Back to Newsroom